Quantification of nicotinic acetylcholine receptors in Parkinson's disease with (123)I-5IA SPECT.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Neurological Sciences

• Publication date

  2007-05-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.JNS.2007.02.014PMID 17367812
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease

  2006cited by this paper
• Different nicotinic acetylcholine receptor subtypes mediating striatal and prefrontal cortical [3H]dopamine release.

  2005cited by this paper
• Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations

  2005cited by this paper
• Subunit Composition of Nicotinic Receptors in Monkey Striatum: Effect of Treatments with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine or l-DOPA

  2005cited by this paper
• 5-[123I]Iodo-A-85380: assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects

  2004cited by this paper
• Nicotinic Acetylcholine Receptor Distribution in Alzheimer's Disease, Dementia with Lewy Bodies, Parkinson's Disease, and Vascular Dementia: In Vitro Binding Study Using 5-[125I]-A-85380

  2004cited by this paper
• Neuronal nicotinic receptors: from structure to pathology.

  2004cited by this paper
• Nicotinic receptors and cognition in Parkinson’s Disease: the importance of neuronal synchrony

  2004cited by this paper
• Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.

  2004cited by this paper
• Quantification of human nicotinic acetylcholine receptors with 123I-5IA SPECT.

  2004cited by this paper
• Regional cerebral blood flow in Parkinson's disease with and without dementia

  2003cited by this paper
• L-DOPA treatment modulates nicotinic receptors in monkey striatum.

  2003cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)

  2003cited by this paper
• Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET

  2003cited by this paper
• Nicotinic receptors in aging and dementia.

  2002cited by this paper
• Evaluation of radioiodinatedS-iodo-3-(2(S)-anotidinyimethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors

  2002cited by this paper
• An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.

  2001cited by this paper
• The pedunculopontine nucleus and Parkinson's disease.

  2000cited by this paper
• Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: Compartment analysis for β‐CFT binding with positron emission tomography

  1999cited by this paper
• An algorithm (decision tree) for the management of Parkinson’s disease (2001):

  1998cited by this paper
• Dopamine D1-Like Receptor Activation Excites Rat Striatal Large Aspiny Neurons In Vitro

  1998cited by this paper
• Presynaptic Nicotinic Modulation of Dopamine Release in the Three Ascending Pathways Studied by In Vivo Microdialysis: Comparison of Naive and Chronic Nicotine‐Treated Rats

  1997cited by this paper
• Presynaptic nicotinic ACh receptors.

  1997cited by this paper
• Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes.

  1996cited by this paper
• Effects of serotonergic agents on neuronal nicotinic acetylcholine receptors.

  1995cited by this paper
• Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology.

  1995cited by this paper
• Statistical parametric maps in functional imaging: A general linear approach

  1994cited by this paper
• What features improve the accuracy of clinical diagnosis in Parkinson's disease

  1992cited by this paper
• Mesocorticolimbic dopaminergic network: functional and regulatory roles.

  1991cited by this paper
• A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease.

  1991cited by this paper
• Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects

  1990cited by this paper
• Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268

  1990cited by this paper
• Unified Parkinson's Disease Rating Scale

  1987cited by this paper
• Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale

  1987cited by this paper
• Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow.

  1986cited by this paper
• Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons.

  1985cited by this paper
• Strategy for the Measurement of Regional Cerebral Blood Flow Using Short-Lived Tracers and Emission Tomography

  1984cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• Parkinsonism

  1967cited by this paper

• Nicotine Ameliorates α-Synuclein Preformed Fibril-Induced Behavioral Deficits and Pathological Features in Mice

  2025cites this paper
• Cortical α4β2-nicotinic acetylcholine receptors and cognitive decline in Parkinson’s disease

  2025cites this paper
• New objective simple evaluation methods of amyloid PET/CT using whole-brain histogram and Top20%-Map

  2024cites this paper
• Visual hallucinations in Parkinson’s disease: spotlight on central cholinergic dysfunction

  2024cites this paper
• Nicotinic acetylcholine receptors in neurological and psychiatric diseases.

  2023cites this paper
• Mapping neuromodulatory systems in Parkinson’s disease: lessons learned beyond dopamine

  2022cites this paper
• The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain

  2021cites this paper
• Parkinson’s Disease

  2020cites this paper
• Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine

  2020cites this paper
• Noninvasive evaluation of nicotinic acetylcholine receptor availability in mouse brain using single-photon emission computed tomography with [I]5IA Short title: [I]5IA-SPECT in the mouse brain

  2020cites this paper
• Spatial Patterns of Amyloid Deposition in Patients with Chronic Focal or Diffuse Traumatic Brain Injury Using 18F-FPYBF-2 PET

  2020cites this paper
• NDT_A_268504 2719..2732

  2020cites this paper
• Cholinergic Mechanisms of Gait Dysfunction in Parkinson’s Disease

  2020cites this paper
• Nigrostriatal Dopaminergic Dysfunction and Altered Functional Connectivity in REM Sleep Behavior Disorder With Mild Motor Impairment

  2019cites this paper
• Misery perfusion and amyloid deposition in atherosclerotic major cerebral artery disease

  2019cites this paper
• 18F-FPYBF-2, a new F-18-labelled amyloid imaging PET tracer: first experience in 61 volunteers and 55 patients with dementia

  2018cites this paper
• Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein.

  2018cites this paper
• Molecular Imaging of the Cholinergic System in Parkinson's Disease.

  2018cites this paper
• In Vivo Imaging of Nicotinic Acetylcholine Receptors in the Central Nervous System

  2018cites this paper
• Neurological Alterations in Cognitive Impairment

  2017cites this paper
• Imaging in Parkinson's Disease.

  2017cites this paper
• Cholinergic activity and levodopa‐induced dyskinesia: a multitracer molecular imaging study

  2017cites this paper
• Imaging in Parkinson's Disease.

  2017cites this paper
• In Vivo Molecular Imaging.

  2017cites this paper
• Cholinergic imaging in dementia spectrum disorders

  2016cites this paper
• Title Page Nicotinic acetylcholine receptors expressed in the ventral posterolateral thalamic nucleus play an important role in antiallodynic effects Running title: NAChRs in the VPL mediate antiallodynic effects

  2016cites this paper
• Noninvasive evaluation of nicotinic acetylcholine receptor availability in mouse brain using single-photon emission computed tomography with [(123)I]5IA.

  2016cites this paper
• Simultaneous imaging and relative quantitation of multiple neurotransmitters in a progressive Parkinson ’ s disease model by MALDI mass spectrometry

  2016cites this paper
• Neurotransmitter receptor density changes in Pitx3ak mice--a model relevant to Parkinson's disease.

  2015cites this paper
• Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson's disease

  2014cites this paper
• Radioligand imaging of α4β2* nicotinic acetylcholine receptors in Alzheimer's disease and Parkinson's disease.

  2014cites this paper
• Recent Progress of Imaging Agents for Parkinson's Disease

  2014cites this paper
• Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson’s Disease

  2014cites this paper
• Presynaptic Nicotinic Acetylcholine Receptors and the Modulation of Circuit Excitability

  2014cites this paper
• SPECT radiopharmaceuticals for dementia.

  2014cites this paper
• The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease

  2013cites this paper
• Functional neuroimaging in Parkinson's disease.

  2012cites this paper
• Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

  2012influential citation
• Imaging beyond the striatonigral dopaminergic system in Parkinson's disease.

  2012cites this paper
• Can nicotine be used medicinally in Parkinson’s disease?

  2011cites this paper
• In vivo relationship between thalamic nicotinic acetylcholine receptor occupancy rates and antiallodynic effects in a rat model of neuropathic pain: Persistent agonist binding inhibits the expression of antiallodynic effects

  2011cites this paper
• Single Photon Emission Computed Tomography (SPECT) Experience with (S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-[123I]IA) in the Living Human Brain of Smokers and Nonsmokers

  2011cites this paper
• Nicotinic acetylcholine receptors expressed in the ventralposterolateral thalamic nucleus play an important role in anti‐allodynic effects

  2010cites this paper
• Smoking, nicotine and neuropsychiatric disorders.

  2010cites this paper
• Efeito da nicotina na ativação do fator de transcrição NF-B no sistema nervoso central na vigência de estímulo inflamatório induzido por lipopolissacarídeo (LPS)

  2009cites this paper
• In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia.

  2009cites this paper
• Decrease of Nicotinic Receptors in the Nigrostriatal System in Parkinson's Disease

  2009cites this paper
• ΠANEΠIΣTHMIO ΠATPΩN ΣXOΛH EΠIΣTHMΩN YΓEIAΣ TMHMA IATPIKHΣ

  2009cites this paper
• Central in vivo nicotinic acetylcholine receptor imaging agents for positron emission tomography (PET) and single photon emission computed tomography (SPECT).

  2009cites this paper
• Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease.

  2009cites this paper
• Reduced (cid:1) 4 (cid:2) 2 * –Nicotinic Acetylcholine Receptor Binding and Its Relationship to Mild Cognitive and Depressive Symptoms in Parkinson Disease

  2009influential citation
• Single photon emission computed tomography experience with (S)‐5‐[123I]iodo‐3‐(2‐azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers

  2009cites this paper
• Discovery of (-)-7-methyl-2-exo-[3'-(6-[18F]fluoropyridin-2-yl)-5'-pyridinyl]-7-azabicyclo[2.2.1]heptane, a radiolabeled antagonist for cerebral nicotinic acetylcholine receptor (alpha4beta2-nAChR) with optimal positron emission tomography imaging properties.

  2008cites this paper
• 5-Iodo-A-85380, a specific ligand for alpha 4 beta 2 nicotinic acetylcholine receptors, prevents glutamate neurotoxicity in rat cortical cultured neurons.

  2008cites this paper
• [Case of a 30-year history of PARK6 --findings from functional imaging of the brain].

  2008cites this paper
• Drugs used to treat Parkinson's disease, present status and future directions.

  2008cites this paper
• ΠΑΝΕΠΙΣΤΗΜΙΟ ΠΑΤΡΩΝ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ

  2005cites this paper